As a control, we introduced the same inoculum dose of Ad-OVA by subcutaneous (SubQ) route in order to initiate CD8+ T cell response through secondary lymphoid tissue presentation within the lymph nodes draining the site of virus infection. Here, CD8A is linked to viral infectious disease.